Eledon Pharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview

Eledon Pharmaceuticals

26/03/2024 20:16

* Eledon Pharmaceuticals Inc  ELDN.OQ   ELDN.O  is expected
to show no change in quarterly revenue when it reports 
results on March 28 (estimated) for the period ending December
31 2023
    * 
    * ​LSEG's mean analyst estimate for Eledon Pharmaceuticals
Inc is
for a loss of 39 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $10.00​, above​ its last closing price
of $2.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.50       -0.46      -0.35     Beat    24
 Jun. 30 2023  -0.46       -0.46      -0.40     Beat    12.8
 Mar. 31 2023  -0.58       -0.60      -0.75     Missed  -25.2​
 Dec. 31 2022  -0.78       -0.70      -0.69     Beat    1.6
 ​​Sep.        -0.68       -0.68      -0.73     Missed  -7.4
 30 2022                                                
 Jun. 30 2022  -0.70       -0.70      -0.65     Beat    7.7​
 Mar. 31 2022  -0.67       -0.68      -0.69     Missed  -1.8
 Dec. 31 2021              -0.75      -0.59     Beat    21.3
 This summary was machine generated March 26 at 20:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)